| US | Spain | Australia | Belgium |
---|---|---|---|---|
Patients, n | 532 | 1,345 | 784 | 408 |
Patients who completed 24 months of treatment (evaluated for clinical measures) | ||||
   Patients with 24 months of follow-up, n (%)a | 209 (39.3) | 843 (62.7) | 359 (45.8) | 262 (64.2) |
   Age in years, mean (SD) | 42.4 (12.3) | 38.8 (11.2) | 39.3 (13.0) | 41.3 (13.3) |
   Male gender, % | 64.1 | 63.2 | 68.5 | 63.7 |
   Years since diagnosis, mean (SD) | 18.1 (11.3) | 13.1 (9.8) | 12.2 (10.4) | 10.6 (10.6) |
   CGI-S score, mean (SD) | 4.6 (1.3) | 4.6 (0.9) | 4.5 (1.0) | 4.7 (1.0) |
   GAF score, mean (SD) | 48.3 (14.6) | 47.8 (15.6) | 42.3 (14.5) | 43.3 (12.0) |
Patients with ≥1 post-baseline visit (evaluated for psychiatric hospitalization rate) | ||||
   Patients with ≥1 post-baseline visit, n (%)a | 435 (81.8) | 1,339 (99.6) | 734 (93.6) | 393 (96.3) |
   Age in years, mean (SD) | 41.9 (12.6) | 38.4 (11.2) | 37.1 (12.5) | 40.3 (13.3) |
   Male gender, % | 66.7 | 63.6 | 69.9 | 62.8 |
   Years since diagnosis, mean (SD) | 17.6 (12.1) | 12.6 (9.5) | 10.7 (9.5) | 9.5 (10.2) |
   Hospitalized in the year before RLAT initiation, % | 39.3 | 35.0 | 76.8 | 71.2 |
   CGI-S score, mean (SD) | 3.9 (1.2) | 4.6 (0.9) | 4.6 (1.0) | 4.7 (1.0) |
   GAF score, mean (SD) | 53.1 (13.7) | 46.9 (15.2) | 42.7 (14.4) | 43.6 (12.5) |